1. Male or female, aged ≥18 years and ≤75 years at the time of signing informed consent；

2. BMI ≥28 kg/m2；

3. A self-reported change in body weight no more than 5% within 90 days before screening.

1. History of type 1 and type 2 diabetes;

2. Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device;

3. History or presence of chronic or acute pancreatitis;

4. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma;

5. A history or presence of suspected depression or other mental disorders;

6. Patient Health Questionnaire-9 score of ≥15 at screening

7. Uncontrolled hypertension, any of the following: myocardial infarction, stroke, hospitalisation for unstable angina, or transient ischaemic attack within the past 6 months prior to screening;

8. History of malignant neoplasms within the past 5 years prior to screening;